PHILLIP SECURITIES |
UOB KAYHIAN |
Singapore REITs Monthly
Valuations are cheap ▪ The S-REITs Index fell 2.9% in February 2025, after gaining 0.2% in the previous month. The top performer for the month was Paragon REIT (PGNREIT SP, non-rated), gaining 9% after the proposed privatisation offer of S$0.98 in cash. The worst performer was Manulife US REIT (MUST SP, non-rated), falling 23.2%, as financial metrics remain stretched. The overseas retail sub-sector was the top performer in February, gaining 1.4%, while the worst-performing sub-sector was overseas commercial, falling 10.3%.
|
Hong Leong Asia (HLA SP) Attractive Valuations Despite Recent Rise In Share Price Performance
HLA is set to post strong earnings growth for 2025-27, driven by its two main business segments. With a significant market share across its key markets, the building materials segment faces a robust pipeline of mega infrastructure and HDB projects. The diesel engine segment also faces strong volume growth across new markets. In our view, HLA remains undervalued given the positive outlook for its businesses. Maintain BUY with a higher SOTP-based target price of S$1.46.
|
UOB KAYHIAN |
UOB KAYHIAN |
COSCO SHIPPING Ports (1199 HK) 2024: Core Earnings In Line; Expect Low Single-digit Throughput Growth In 2025
CSP’s 2024 core net profit of US$301.8m (+4.9% yoy) was in line with our expectation, at 101.2% of our forecast. The miss at the operating profit level was more than offset by strong JV/associate performance and interest cost savings from debt refinancing. Management guides CSP’s portfolio equity throughput to grow in line with the industry average at a low-single-digit growth rate in 2025. CSP is trading at 7.6x/7.2x 2025/26F PE and offers decent yields of 5.4%/5.6%. Maintain BUY. Target price: HK$5.90.
|
Meituan (3690 HK) 4Q24: Results In Line; Stable 2025 Margin On Competition And Overseas Expansion
Meituan’s 4Q24 results were in line with expectations. Total revenue grew 20% yoy to Rmb88.5b, in line with our and consensus estimates. Non-IFRS net profit was Rmb6.2b, with net margin expanding 5ppt yoy to 11%, in line with consensus forecasts. For 2025, we are cautiously optimistic on Meituan in view of solid progress in overseas expansion and AI development, offset by margin pressures due to the intensely competitive landscape. Maintain BUY with a lower target price of HK$216.00.
|
OCBC | DBS RESEARCH |
Summary of Xiaomi Corp Research ReportRating: BUY (as of 21 March 2025) Key Highlights:
Investment Thesis:
|
Here’s a concise summary of the research report: Great Wall of Robots: A Self-Sustained Rise – Robotics Sector
Investment Takeaway:The robotics sector is seeing strong momentum, with China’s market poised for rapid expansion. Xiaomi and BYDE are well-positioned to benefit from this growth, making them top picks over component suppliers. |